Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model

International Journal of Antimicrobial Agents

Volumn 22, Issue 6, 2003, Pages 574-578

  Sauermann, Robert ^a   Zeitlinger, Markus ^a   Erovic, Boban M ^a   Marsik, Claudia ^a   Georgopoulos, Apostolos ^b   Müller, Markus ^a   Brunner, Martin ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Pharmacodynamics; Piperacillin; PK PD model

Indexed keywords

ANTIINFECTIVE AGENT; PIPERACILLIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; IN VITRO STUDY; INTENSIVE CARE; KIDNEY FUNCTION; MODEL; PHARMACODYNAMICS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SIMULATION; SOFT TISSUE; STAPHYLOCOCCUS AUREUS; TARGET ORGAN;

EID: 0345549442     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.05.003     Document Type: Article

References (20)

1. Van Dalen R., Vree T.B. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 16:(Suppl 3):1990;S235-S238.
2. Eichler H.G., Müller M. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin. Pharmacokinet. 34:1998;95-99.
3. Schentag J.J., Gengo F.M. Principles of antibiotic tissue penetration and guidelines for pharmacokinetic analysis. Med. Clin. North Am. 66:1982;39-49.
4. Liu P., Müller M., Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int. J. Antimicrob. Agents. 19:2002;285-290.
5. Brunner M., Pernerstorfer T., Mayer B.X., Eichler H.G., Müller M. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit. Care Med. 28:2000;1754-1759.
6. Joukhadar C., Frossard M., Mayer B.X., et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit. Care Med. 29:2001;385-391.
7. Holmes B., Richards D.M., Brogden R.N., Heel R.C. Piperacillin; a review of its antibacterial activity, pharmacokinetic properties and therapeutical use. Drugs. 28:1984;375-425.
8. Charbonneau P. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. Intensive Care Med. 20:(Suppl 3):1994;S43-S48.
9. Delacher S., Derendorf H., Hollenstein U., et al. A combined in vivo PK/in vitro approach to simulate target site pharmacodynamics of antibiotics in humans. J. Antimicrob. Chemother. 46:2000;733-739.
10. Brunner M., Stabeta H., Moller J.G., et al. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 46:2002;3724-3730.
11. Doern V.G., Jones R.N., Pfaller M.A., Kugler K.C., Beach M.L. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Program (United States and Canada, 1997). SENTRY Study Group, (North America). Diagn. Microbiol. Infect. Dis. 34:1999;65-72.
12. Jones M.E., Schmitz F.J., Fluit A.C., Acar J., Gupta R., Verhoef J. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during from an international surveillance program. SENTRY Participants Group 1997. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;403-408.
13. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved Standard, M7-A4. Wayne, PA: NCCLS, 1997.
14. Kennedy M., Van Riji A. Effects of surgery on the pharmacokinetic parameters of drugs. Clin. Pharmacokinet. 35:1998;293-312.
15. Derendorf H., Dalla Costa T. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Int. J. Clin. Pharmacol. Ther. 34:1996;482-488.
16. Kinzig M., Sörgel F., Brismar B., Nord C.E. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 36:1992;1997-2004.
17. Joukhadar C., Klein N., Mayer B.X., et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit. Care Med. 30:2002;1478-1482.
18. Bryson H.M., Brogden R.N. Piperacillin/Tazobactam. A review of its activity, pharmacokinetic properties and therapeutic potential. Drugs. 47:1994;506-535.
19. Hyatt J.M., McKinnon P.S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinet. 28:1995;143-160.
20. Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int. J. Antimicrob. Agents. 17:2001;1-8.